Biomarker Predicts Recurrence and Benefit from Letrozole After Tamoxifen in ER-positive Breast Cancer

Researchers have identified a biomarker that indicates a high risk of late recurrence in patients with breast cancer, and helps identify those who will benefit from letrozole therapy.